LINCOLN636.70

Lincoln Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,275 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations580.5623.2671.0694.2
Other Income34.422.533.542.4
Total Income615.0645.7704.5736.7
Expenses
+ Cost of Materials Consumed201.1213.9239.6237.2
+ Purchases of Stock-in-Trade82.968.579.084.1
+ Changes in Inventories-5.78.8-7.45.6
+ Employee Benefit Expense102.9112.5125.2126.7
+ Finance Costs1.51.91.01.1
+ Depreciation & Amortisation10.612.914.514.9
+ Other Expenses99.4118.0137.0139.3
Total Expenses492.7536.5588.9608.9
EBITDA99.9101.597.7101.3
EBIT89.388.683.286.4
Profit
PBT before Exceptional Items122.2109.2115.6127.8
Pretax Income122.2109.2115.6127.8
+ Current Tax25.425.327.828.5
+ Deferred Tax3.51.5-0.02.8
Tax Expense28.926.827.731.3
Net Income93.382.387.996.5
+ Net Income — Continuing Ops93.382.387.996.5
+ Other Comprehensive Income0.10.11.72.1
Total Comprehensive Income93.482.489.698.5
Per Share
Basic EPS46.5841.1143.8848.16
Diluted EPS46.5841.1143.8848.16
Other Comprehensive Income — detail
+ Other Comprehensive Income0.11.72.1
+ Tax on Items NOT to be Reclassified-0.1-1.7-2.1
Comprehensive Income — Owners of Parent0.00.10.036.3
Per Share — as-filed variants
Basic EPS — Continuing Operations46.5841.1143.8848.16
Diluted EPS — Continuing Operations46.5841.1143.8848.16
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit302.2331.9359.9367.3
Gross Margin %52.0653.2653.6352.91
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)122.2109.2115.6127.8
Net Income Adj (tax-effected)93.382.387.996.5
EPS Adj46.5841.1143.8848.16
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital20.020.020.020.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.